(CROX) Crocs - Overview
Sector: Consumer Cyclical | Industry: Footwear & Accessories | Exchange: NASDAQ (USA) | Market Cap: 5.897m USD | Total Return: 16.7% in 12m
Avg Turnover: 128M
EPS Trend: 49.3%
Qual. Beats: 16
Rev. Trend: 67.8%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
Idiosyncratic Leader
Crocs, Inc. (NASDAQ: CROX) is a global designer and distributor of casual lifestyle footwear, operating primarily through its namesake Crocs brand and the HEYDUDE acquisition. The company utilizes a multi-channel distribution strategy encompassing wholesale, company-operated retail, and direct-to-consumer e-commerce platforms.
The business model relies heavily on high-margin proprietary materials, such as Croslite, which allow for low-cost manufacturing and high product durability. In the footwear sector, brand loyalty is often driven by such functional differentiation and the ability to scale through high-volume, injection-molded production processes.
The product portfolio extends beyond clogs into sandals, boots, and licensed accessories, targeting a broad demographic of men, women, and children. For a deeper look into the companys financial health, you may want to examine the latest valuation metrics on ValueRay.
Headquartered in Broomfield, Colorado, the firm maintains an international footprint with a significant presence in both established Western markets and emerging regions. This geographic diversification helps mitigate regional retail volatility inherent in the consumer discretionary sector.
- HEYDUDE brand integration and wholesale stabilization drive overall revenue growth trajectory
- International market expansion in China and Asia-Pacific fuels top-line diversification
- Direct-to-consumer digital channel growth improves consolidated operating margins
- Raw material cost fluctuations and global shipping logistics impact gross profitability
- High-profile product collaborations and Jibbitz sales sustain brand relevance and demand
| Net Income: -103.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA -2.01 > 1.0 |
| NWC/Revenue: 10.58% < 20% (prev 8.99%; Δ 1.58% < -1%) |
| CFO/TA 0.17 > 3% & CFO 724.5m > Net Income -103.7m |
| Net Debt (1.98b) to EBITDA (946.5m): 2.10 < 3 |
| Current Ratio: 1.67 > 1.5 & < 3 |
| Outstanding Shares: last quarter (50.7m) vs 12m ago -10.26% < -2% |
| Gross Margin: 58.10% > 18% (prev 59.25%; Δ -1.15% > 0.5%) |
| Asset Turnover: 85.55% > 50% (prev 80.95%; Δ 4.60% > 0%) |
| Interest Coverage Ratio: 10.07 > 6 (EBIT TTM 865.5m / Interest Expense TTM 86.0m) |
| A: 0.10 (Total Current Assets 1.07b - Total Current Liabilities 639.5m) / Total Assets 4.34b |
| B: 0.83 (Retained Earnings 3.62b / Total Assets 4.34b) |
| C: 0.18 (EBIT TTM 865.5m / Avg Total Assets 4.70b) |
| D: 0.49 (Book Value of Equity 1.43b / Total Liabilities 2.92b) |
| Altman-Z'' = 5.11 = AAA |
| DSRI: 1.02 (Receivables 470.1m/469.9m, Revenue 4.02b/4.10b) |
| GMI: 1.02 (GM 59.25% / 58.10%) |
| AQI: 0.92 (AQ_t 0.62 / AQ_t-1 0.67) |
| SGI: 0.98 (Revenue 4.02b / 4.10b) |
| TATA: -0.19 (NI -103.7m - CFO 724.5m) / TA 4.34b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of June 08, 2026, the stock is trading at USD 119.35 with a total of 1,082,482 shares traded.
Over the past week, the price has changed by +0.57%,
over one month by +14.67%,
over three months by +36.93% and
over the past year by +16.74%.
Crocs has received a consensus analysts rating of 4.20. Therefore, it is recommended to buy CROX.
- StrongBuy: 7
- Buy: 4
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 112.7 | -5.6% |
P/E Forward = 8.6281
P/S = 1.4651
P/B = 4.1311
P/EG = 1.3926
Revenue TTM = 4.02b USD
EBIT TTM = 865.5m USD
EBITDA TTM = 946.5m USD
Long Term Debt = 1.33b USD (from longTermDebt, last quarter)
Short Term Debt = 93.8m USD (from shortTermDebt, last quarter)
Debt = 2.12b USD (from shortLongTermDebtTotal, last quarter) + Leases 389.6m
Net Debt = 1.98b USD (calculated: Debt 2.12b - CCE 130.9m)
Enterprise Value = 7.88b USD (5.90b + Debt 2.12b - CCE 130.9m)
Interest Coverage Ratio = 10.07 (Ebit TTM 865.5m / Interest Expense TTM 86.0m)
EV/FCF = 11.75x (Enterprise Value 7.88b / FCF TTM 670.7m)
FCF Yield = 8.51% (FCF TTM 670.7m / Enterprise Value 7.88b)
FCF Margin = 16.66% (FCF TTM 670.7m / Revenue TTM 4.02b)
Net Margin = -2.58% (Net Income TTM -103.7m / Revenue TTM 4.02b)
Gross Margin = 58.10% ((Revenue TTM 4.02b - Cost of Revenue TTM 1.69b) / Revenue TTM)
Gross Margin QoQ = 56.75% (prev 54.68%)
Tobins Q-Ratio = 1.81 (Enterprise Value 7.88b / Total Assets 4.34b)
Interest Expense / Debt = 4.07% (Interest Expense 86.0m / Debt 2.12b)
Taxrate = 23.09% (41.3m / 178.8m)
NOPAT = 665.7m (EBIT 865.5m * (1 - 23.09%))
Current Ratio = 1.67 (Total Current Assets 1.07b / Total Current Liabilities 639.5m)
Debt / Equity = 1.48 (Debt 2.12b / totalStockholderEquity, last quarter 1.43b)
Debt / EBITDA = 2.10 (Net Debt 1.98b / EBITDA 946.5m)
Debt / FCF = 2.96 (Net Debt 1.98b / FCF TTM 670.7m)
Total Stockholder Equity = 1.38b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.21% (Net Income -103.7m / Total Assets 4.34b)
RoE = -7.54% (Net Income TTM -103.7m / Total Stockholder Equity 1.38b)
RoCE = 31.98% (EBIT 865.5m / Capital Employed (Equity 1.38b + L.T.Debt 1.33b))
RoIC = 18.15% (NOPAT 665.7m / Invested Capital 3.67b)
WACC = 8.55% (E(5.90b)/V(8.01b) * Re(10.49%) + D(2.12b)/V(8.01b) * Rd(4.07%) * (1-Tc(0.23)))
Discount Rate = 10.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -95.56 | Cagr: -7.87%
[DCF] Terminal Value 72.36% ; FCFF base≈755.9m ; Y1≈662.9m ; Y5≈535.6m
[DCF] Fair Price = 127.7 (EV 8.33b - Net Debt 1.98b = Equity 6.34b / Shares 49.7m; r=8.55% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 49.31 | EPS CAGR: 2.23% | SUE: 1.25 | # QB: 16
Revenue Correlation: 67.85 | Revenue CAGR: 1.37% | SUE: 1.20 | # QB: 3
EPS current Quarter (2026-06-30): EPS=4.31 | Chg30d=+0.62% | Revisions=+12% | Analysts=14
EPS next Quarter (2026-09-30): EPS=3.54 | Chg30d=+1.78% | Revisions=+38% | Analysts=13
EPS current Year (2026-12-31): EPS=13.65 | Chg30d=+2.71% | Revisions=+58% | GrowthEPS=+9.1% | GrowthRev=+0.6%
EPS next Year (2027-12-31): EPS=14.52 | Chg30d=+2.40% | Revisions=+58% | GrowthEPS=+6.3% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +58%